Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dicerna Pharmaceuticals, Inc. Announces Poster Presentations at American Association for the Study of Liver Diseases The Liver Meeting® 2021 in November

10/14/2021 | 04:54pm EST

Dicerna Pharmaceuticals, Inc. announced that two abstracts related to the Company’s clinical development programs have been accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® taking place Nov. 12-15, 2021. The first abstract provides clinical data from the Company’s Phase 1 trial of belcesiran, an investigational GalXC™ RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD). Session: Metabolic and Genetic Disease: Hemochromatosis, Wilson Disease, a-1 Antitrypsin Deficiency; Poster Title: Belcesiran Was Well-Tolerated and Reduced Serum AAT Levels in Healthy Volunteers (Phase 1 Interim Results); Poster #: 27962; and Abstract #: 1549. An additional abstract provides results of a subpopulation pharmacokinetic and safety analysis from the Phase 1 trial of RG6346 (RO7445482), an investigational GalXC RNAi therapeutic that Dicerna is developing in collaboration with Roche for the treatment of chronic hepatitis B virus (HBV) infection. Session: Hepatitis B: Therapeutics: New Agents; Poster Title:The Pharmacokinetic and Safety Profiles of RO7445482 siRNA Are Similar Between Asian and Non-Asian Healthy Volunteers and Chronic Hepatitis B Patients in a Phase 1 Study; Poster #: 28577; and Abstract #: 850. Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.


© S&P Capital IQ 2021
All news about DICERNA PHARMACEUTICALS, INC.
11/22INSIDER SELL : Dicerna Pharmaceuticals
MT
11/22SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Dicerna Pharm..
PR
11/22Stifel Downgrades Dicerna Pharmaceuticals to Hold From Buy, Adjusts Price Target to $38..
MT
11/22Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day..
MT
11/22NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/19B. Riley Downgrades Dicerna Pharmaceuticals to Neutral from Buy After Announcing $3.3 B..
MT
11/19RBC Downgrades Dicerna Pharmaceuticals to Sector Perform From Outperform, Lifts PT to $..
MT
11/18SHAREHOLDER ALERT : WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.
PR
11/18HC Wainwright Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts PT to $38..
MT
11/18Health Care Stocks Ending Little Changed in Quiet Trading
MT
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 193 M - -
Net income 2021 -127 M - -
Net cash 2021 544 M - -
P/E ratio 2021 -23,4x
Yield 2021 -
Capitalization 2 977 M 2 977 M -
EV / Sales 2021 12,6x
EV / Sales 2022 13,5x
Nbr of Employees 302
Free-Float 92,8%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 38,10 $
Average target price 34,96 $
Spread / Average Target -8,23%
EPS Revisions
Managers and Directors
Douglas M. Fambrough President, Chief Executive Officer & Director
Douglas W. Pagán Chief Financial Officer
J. Kevin Buchi Chairman
Bob D. Brown Chief Scientific Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.72.95%2 977
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.26.13%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122